Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition (Vivifrail)

1 de septiembre de 2026 actualizado por: Alessandra Quadros, Federal University of Rio Grande do Sul

Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial

This randomized clinical trial investigates the effects of a home-based multicomponent exercise program (Vivifrail) on physical function, muscle morphology, and cognition in community-dwelling adults aged 90 years and older. Participants are randomized into three groups: Vivifrail at least twice a week, Vivifrail at least three times a week, or a control group. Outcomes are assessed at baseline, 12 weeks, and 24 weeks. The primary outcome is physical function measured by the Short Physical Performance Battery (SPPB).

Descripción general del estudio

Estado

Inscripción por invitación

Descripción detallada

This is a three-arm, parallel-group randomized controlled trial evaluating a home-based multicomponent exercise program based on the Vivifrail protocol in community-dwelling nonagenarians (aged 90 years or older). A total of 54 participants (18 per group) will be randomly allocated to one of three groups: G1, performing the Vivifrail program at least twice a week; G2, performing it at least three times a week; or a control group (GC) maintaining usual activities.

Randomization will be performed using Randomizer software (www.randomizer.org) by an independent researcher not involved in the assessments. Allocation is stratified by sex and by baseline functional level, defined by collapsing the six Vivifrail functional categories into two groups (lower function: Types A, B, and B+; higher function: Types C, C+, and D), to ensure balanced distribution of baseline physical function across the three groups. Each participant is still assigned the individualized Vivifrail training passport corresponding to their specific functional category. Given the autonomous, home-based nature of the intervention, participants and interventionists cannot be blinded; however, outcome assessors remain blinded to group allocation throughout the study.

Assessments occur at three timepoints: baseline (T0), 12 weeks (T1), and 24 weeks (T2). The 24-week intervention is individualized according to each participant's functional profile, determined by the Short Physical Performance Battery (SPPB) and the corresponding Vivifrail training passport.

The primary outcome is physical function measured by the total SPPB score (0-12). Secondary outcomes include mobility (Timed Up and Go and cognitive dual-task cost), handgrip strength, lower-limb power (five-times sit-to-stand with linear encoder), gait speed, balance, muscle morphology of the vastus lateralis (ultrasound), cognition (Mini-Mental State Examination), and change in Vivifrail functional category. Data will be analyzed by intention to treat using generalized estimating equations (GEE), examining the group-by-time interaction.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

54

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Hospital de Clínicas de Porto Alegre (HCPA) - Geriatrics outpatient clinic
      • Porto Alegre, Rio Grande do Sul, Brasil, 90690-200
        • Escola de Educação Física, Fisioterapia e Dança (ESEFID/UFRGS) - and participants' homes

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Aged 90 years or older
  • Living in the community (own or family home)
  • Able to walk independently or with a walking aid (cane or walker), without third-party assistance
  • Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)
  • Adequate home conditions to perform the program
  • Availability of a family member or caregiver to support the sessions
  • Signed informed consent (with legal guardian assistance when needed)

Exclusion Criteria:

  • - Total inability to walk or permanent bedridden condition
  • Severe cognitive impairment preventing safe understanding and execution of exercises
  • Severe orthopedic, neurological, or rheumatological conditions preventing exercise
  • Concurrent participation in another structured exercise program
  • Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention
  • Refusal to sign informed consent or absence of a legal guardian when required

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Vivifrail - 2 sessions/week (G1)
Home-based Vivifrail multicomponent exercise program performed at least twice a week for 24 weeks, individualized by functional profile (SPPB and Vivifrail passport).
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
Experimental: Vivifrail - 3 sessions/week (G2)
Home-based Vivifrail multicomponent exercise program performed at least three times a week for 24 weeks, individualized by functional profile.
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
Sin intervención: Control (GC)
Participants maintain usual activities without a structured exercise program during the 24-week period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in physical function measured by the Short Physical Performance Battery (SPPB) total score
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Total SPPB score ranging from 0 to 12 points (higher scores indicate better lower-extremity physical function), combining balance, gait speed, and chair-stand tests.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mobility - Timed Up and Go (TUG)
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
ime in seconds to rise, walk 3 meters, turn, return, and sit.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Mobility under dual task - Cognitive TUG and dual-task cost (DTC%) ·
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
TUG performed with a concurrent cognitive task; dual-task cost calculated as percentage change relative to single-task TUG.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Handgrip strength
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Maximal isometric handgrip strength in kilograms, measured with a Jamar dynamometer.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Lower-limb muscle power - Five-times sit-to-stand
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
ime in seconds and estimated lower-limb power measured during the five-times sit-to-stand test using a linear encoder.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Gait speed
Periodo de tiempo: aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Usual gait speed in meters per second.
aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Balance
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Static balance assessed by the SPPB balance component (side-by-side, semi-tandem, and tandem stands).
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
Change in Vastus Lateralis Muscle Thickness
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Vastus lateralis muscle thickness measured by B-mode ultrasound, defined as the distance between the adipose-muscle and muscle-bone interfaces, analyzed in ImageJ by a single trained, blinded assessor.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Change in Vastus Lateralis Echo Intensity (Muscle Quality)
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Muscle quality assessed by echo intensity on B-mode ultrasound, expressed in arbitrary units (grayscale, 0-255) via manual region-of-interest analysis in ImageJ, excluding fascia and bone. Higher echo intensity indicates greater intramuscular fat/fibrous infiltration, i.e., poorer muscle quality. Single assessor blinded to group allocation.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Cognition - Mini-Mental State Examination (MMSE)
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Global cognitive function measured by the MMSE, using education-adjusted cutoffs.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Change in Vivifrail functional category
Periodo de tiempo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
Transition across Vivifrail functional categories (Types A, B, B+, C, C+, D) over the intervention period.
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de julio de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

20 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de julio de 2026

Publicado por primera vez (Actual)

28 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir